Dihydroergotamine Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of dihydroergotamine during breastfeeding. Because it might cause adverse effects in the infant and decrease the milk supply, most authorities consider ergotamine to be contraindicated during nursing.[1-3] The manufacturer of the dihydroergotamine nasal spray recommends that nursing mother should not breastfeed during treatment and for 3 days after the last dose. Any milk that is pumped during this time should be discarded.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Davanzo R, Bua J, Paloni G, et al. Breastfeeding and migraine drugs. Eur J Clin Pharmacol. 2014;70:1313–24. [PubMed: 25217187]
2.
MacGregor EA. Migraine in pregnancy and lactation. Neurol Sci. 2014;35 Suppl 1:61–4. [PubMed: 24867839]
3.
Anderson PO. Migraine drug therapy during breastfeeding. Breastfeed Med. 2019;14:445–7. [PubMed: 31347910]
Substance Identification
Substance Name
Dihydroergotamine
CAS Registry Number
511-12-6
Drug Class
Breast Feeding
Lactation
Analgesics, Non-Narcotic
Dopamine Agonists
Vasoconstrictor Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
